Literature DB >> 28865996

Comparative Perioperative Outcomes in Septuagenarians and Octogenarians Undergoing Radical Cystectomy for Bladder Cancer-Do Outcomes Differ?

Tyler D Haden1, Megan C Prunty1, Alexander B Jones1, Chelsea B Deroche1, Katie S Murray1, Naveen Pokala2.   

Abstract

BACKGROUND: Treatment choice for muscle invasive bladder cancer continues to be radical cystectomy. However, radical cystectomy carries a relatively high risk of morbidity and mortality compared with other urological procedures.
OBJECTIVE: To compare surgical complications following radical cystectomy in septuagenarians and octogenarians. DESIGN, SETTING, AND PARTICIPANTS: The National Surgical Quality Improvement Program database (2009-2013) was used to identify patients who were 70 yr and older and underwent radical cystectomy. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The data were analyzed for demographics and comorbidities, and compared for complications, including pulmonary, thromboembolic, wound, and cardiac complications. Patients who were 70-79 yr of age were compared with those 80 yr and older. Univariate and multivariate analyses were completed. RESULTS AND LIMITATIONS: A total of 1710 patients aged ≥70 yr met our inclusion criteria. Of them, 28.8% (n=493) were 80 yr and older, while 71.2% (n=1217) were between 70 and 79 yr old. Operative time (338.4 vs 307.2min, p=0.0001) and the length of stay (11.9 vs 10.4 d, p=0.0016) were higher in the octogenarian group. The intra- and postoperative transfusion rates, reoperative rates, wound dehiscence rates, and pneumonia, sepsis, and myocardial infarction rates were similar between the two groups. The wound infection rate (7.3% vs 4.1%, p=0.01) was higher in the septuagenarians and mortality rate (4.3% vs 2.3%, p=0.04) was higher in the octogenarian group.
CONCLUSIONS: Radical cystectomy can safely be performed in octogenarians without increased cardiac, pulmonary, and thromboembolic complications when compared with septuagenarians. These patients need to be counseled that the mortality rate is slightly higher compared with that in septuagenarians. Chronological age alone should not be used to decide on offering radical cystectomy. PATIENT
SUMMARY: We looked at complications following radical cystectomy in patients aged 80 yr and older. We found that there was no significant difference for wound, cardiac, or pulmonary complications, but there was an increased risk of mortality in this age group.
Copyright © 2017 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Complications; Muscle invasive bladder cancer; Octogenarians; Radical cystectomy; Septuagenarians

Mesh:

Year:  2017        PMID: 28865996     DOI: 10.1016/j.euf.2017.08.005

Source DB:  PubMed          Journal:  Eur Urol Focus        ISSN: 2405-4569


  4 in total

1.  Experience of surgeon, hospital, and comprehensive cancer team critical to the outcomes of radical cystectomy and urinary diversion.

Authors:  Ram Anil Pathak; Ashok Kumar Hemal
Journal:  Transl Androl Urol       Date:  2019-07

2.  Trimodal therapy vs. radical cystectomy for muscle-invasive bladder cancer: A Markov microsimulation model.

Authors:  Diana Magee; Douglas Cheung; Amanda Hird; Srikala S Sridhar; Charles Catton; Peter Chung; Alejandro Berlin; Padraig Warde; Alexandre Zlotta; Neil Fleshner; Girish S Kulkarni
Journal:  Can Urol Assoc J       Date:  2022-04       Impact factor: 2.052

3.  Comparative Analysis of Elderly Patients Undergoing Radical Cystectomy With Ureterocutaneostomy or Ileal Conduit With a Special Focus on Bowl Complications Requiring Surgical Revision.

Authors:  David Mally; Patricia John; David Pfister; Axel Heidenreich; Peter Albers; Günter Niegisch
Journal:  Front Surg       Date:  2022-06-10

4.  Predicting 90-day and long-term mortality in octogenarians undergoing radical cystectomy.

Authors:  Michael Froehner; Rainer Koch; Matthias Hübler; Ulrike Heberling; Vladimir Novotny; Stefan Zastrow; Oliver W Hakenberg; Manfred P Wirth
Journal:  BMC Urol       Date:  2018-10-22       Impact factor: 2.264

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.